Prelude Therapeutics (PRLD) investor relations material

Company overview and strategy

• Focuses on precision oncology, targeting cancers with limited therapeutic options and aiming to deliver genuinely better treatments for underserved patients.

• All pipeline assets are internally discovered and designed to outperform existing therapies.

• Well-capitalized with multiple data catalysts expected in the next 12–24 months.

Pipeline highlights

• PRT12396 (2396) is a selective JAK2 V617F inhibitor in phase I, designed to target mutated JAK2 and reduce toxicities, aiming for disease modification in myeloproliferative neoplasms (MPNs).

• KAT6A selective degrader targets ER+ breast cancer, aiming to improve efficacy and reduce hematological toxicity by sparing KAT6B.

• CALR-targeted antibody-degrader conjugate aims for deeper responses and improved patient-friendly formulations in MPNs.

Clinical development and differentiation

• Phase I for 2396 independently dose escalates in myelofibrosis (MF) and polycythemia vera (PV) to optimize dosing for distinct patient needs.

• Early efficacy signals for 2396 include normalization of blood counts, reduction in mutant allele burden, and symptom improvement.

• Expansion to essential thrombocythemia (ET) is planned after PV dosing is established.

• 2396 is differentiated by its unique chemical space and mechanism, binding deep into the JH2 domain of JAK2 V617F.